Efficacy and tolerability of veliparib (V; ABT-888) in combination with carboplatin (C) and paclitaxel (P) vs placebo (Plc) plus C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer: A randomized, phase 2 study

被引：7
|
作者：
Han, H. S. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ,11 ,12 ,13 ,14 ,15 ,16 ]
Dieras, V. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ,11 ,12 ,13 ,14 ,15 ,16 ]
Robson, M. E. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ,11 ,12 ,13 ,14 ,15 ,16 ]
Palacova, M. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ,11 ,12 ,13 ,14 ,15 ,16 ]
Marcom, P. K. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ,11 ,12 ,13 ,14 ,15 ,16 ]
Jager, A. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ,11 ,12 ,13 ,14 ,15 ,16 ]
Bondarenko, I. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ,11 ,12 ,13 ,14 ,15 ,16 ]
Citrin, D. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ,11 ,12 ,13 ,14 ,15 ,16 ]
Campone, M. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ,11 ,12 ,13 ,14 ,15 ,16 ]
Telli, M. L. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ,11 ,12 ,13 ,14 ,15 ,16 ]
Domchek, S. M. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ,11 ,12 ,13 ,14 ,15 ,16 ]
Friedlander, M. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ,11 ,12 ,13 ,14 ,15 ,16 ]
Man, B. Kauf [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ,11 ,12 ,13 ,14 ,15 ,16 ]
Ratajczak, C. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ,11 ,12 ,13 ,14 ,15 ,16 ]
Coates, A. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ,11 ,12 ,13 ,14 ,15 ,16 ]
Bonnet, P. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ,11 ,12 ,13 ,14 ,15 ,16 ]
Qin, Q. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ,11 ,12 ,13 ,14 ,15 ,16 ]
Qian, J. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ,11 ,12 ,13 ,14 ,15 ,16 ]
Giranda, V. L. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ,11 ,12 ,13 ,14 ,15 ,16 ]
Shepherd, S. P. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ,11 ,12 ,13 ,14 ,15 ,16 ]
Isakoff, S. J. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ,11 ,12 ,13 ,14 ,15 ,16 ]
Puhalla, S. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ,11 ,12 ,13 ,14 ,15 ,16 ]
机构：
[1] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[2] Inst Curie, Paris, France
[3] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[4] Masarykuv Onkol Ustav, Brno, Czech Republic
[5] Duke Univ, Durham, NC USA
[6] Erasmus MC Canc Inst, Rotterdam, Netherlands
[7] Dnepropetrovsk City Hosp, Dnepropetrovsk, Ukraine
[8] Midwestern Reg Med Ctr, Zion, IL USA
[9] Inst Cancerol Ouest, St Herblain, France
[10] Stanford Univ, Sch Med, Stanford, CA USA
[11] Univ Penn, Philadelphia, PA 19104 USA
[12] Prince Wales Hosp, Sydney, NSW, Australia
[13] Sheba Med Ctr, Tel Hashomer, Israel
[14] AbbVie Inc, Chicago, IL USA
[15] Massachusetts Gen Hosp, Boston, MA 02114 USA
[16] Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.SABCS16-S2-05
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
S2-05
引用
收藏
页数：2
相关论文
共 50 条
  • [21] A phase Ib study of sapacitabine (sapa) and olaparib (ola) in patients (pts) with BRCA1/2-mutated (BRCA1/2m) metastatic breast cancer (MBC)
    Lynce, Filipa
    Graham, Noah
    Kochupurakkal, Bose S.
    Huy Nguyen
    Poorvu, Philip D.
    Attaya, Victoria
    Davis, Raechel
    Garg, Kavita
    Lim, Lee P.
    Li, Mark
    Paweletz, Cloud P.
    Tayob, Nabihah
    Shapiro, Geoffrey I.
    Tolaney, Sara M.
    CANCER RESEARCH, 2023, 83 (08)
  • [22] Two phase I trials exploring different dosing schedules of carboplatin (C), paclitaxel (P), and the poly-ADP-ribose polymerase (PARP) inhibitor, veliparib (ABT-888) (V) with activity in triple negative breast cancer (TNBC)
    Puhalla, S. L.
    Appleman, L. J.
    Beumer, J. H.
    Tawbi, H.
    Stoller, R. G.
    Owonikoko, T. K.
    Ramalingam, S. S.
    Belani, C. P.
    Brufsky, A. M.
    Abraham, J.
    Shepherd, S. P.
    Giranda, V.
    Chen, A. P.
    Chu, E.
    CANCER RESEARCH, 2012, 72
  • [23] Safety and efficacy of veliparib plus carboplatin/paclitaxel in patients with HER2-negative metastatic or locally advanced breast cancer: subgroup analyses by germline BRCA1/2 mutations and hormone receptor status from the phase-3 BROCADE3 trial
    Ayoub, Jean-Pierre
    Wildiers, Hans
    Friedlander, Michael
    Arun, Banu K.
    Han, Hyo S.
    Puhalla, Shannon
    Shparyk, Yaroslav
    Jakobsen, Erik H.
    Wu, Meijing
    Bach, Bruce A.
    Feng, Dai
    Ratajczak, Christine K.
    Maag, David
    Dieras, Veronique
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13
  • [24] Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: A genomic resequencing study in the NSABP-P1 Breast Cancer Prevention Trial (BCPT).
    King, MC
    Wieand, HS
    Hale, K
    Walsh, T
    Owens, KM
    Lee, MK
    Costantino, JP
    Fisher, B
    AMERICAN JOURNAL OF HUMAN GENETICS, 2001, 69 (04) : 272 - 272
  • [25] Phase II trial of single agent PARP inhibitor ABT-888 (veliparib [vel]) followed by postprogression therapy of vel with carboplatin (carb) in patients (pts) with stage BRCA-associated metastatic breast cancer (MBC): California Cancer Consortium trial PHII-96
    Somlo, George
    Frankel, Paul Henry
    Luu, Thehang H.
    Ma, Cynthia
    Arun, Banu
    Garcia, Agustin
    Cigler, Tessa
    Cream, Leah
    Harvey, Harold A.
    Sparano, Joseph A.
    Nanda, Rita
    Chew, Helen K.
    Moynihan, Timothy Jerome
    Vandat, Linda T.
    Goetz, Matthew P.
    Hurria, Arti
    Mortimer, Joanne E.
    Gandara, David R.
    Chen, Alice
    Weitzel, Jeffrey N.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [26] Outcome of BRCA 1/2-mutated (BRCA plus ) and triple-negative, BRCA, wild type (BRCA-wt) breast cancer patients in a phase I study of single-agent veliparib (V)
    Pahula, Shalu
    Beumer, Jan Hendrik
    Appleman, Leonard Joseph
    Tawbi, Hussein Abdul-Hassan
    Stoller, Ronald G.
    Lee, James J.
    Lin, Yan
    Kiesel, Brian
    Yu, Jing
    Tan, Antoinette R.
    Belani, Chandra Prakash
    Chew, Helen K.
    Garcia, Agustin A.
    Morgan, Robert
    Chen, Alice P.
    Giranda, Vincent L.
    Shepherd, Stacie Peacock
    Chu, Edward
    Puhalla, Shannon
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (26)
  • [27] Phase IV study evaluating effectiveness and safety of talazoparib in patients with locally advanced or metastatic HER2 negative breast cancer and a BRCA1 or BRCA2 mutation (ViTAL)
    Loirat, Delphine
    de labarre, Marie Duboys
    Essner, Christine
    Hrab, Ioana
    Thery, Jean-Christophe
    Jouannaud, Christelle
    Vuagnat, Perrine
    Soibinet-Oudot, Pauline
    Creisson, Anne
    Mailliez, Audrey
    Mouysset, Jean-Loup
    Salabert, Laura
    Dohollou, Nadine
    Fumet, Jean-David
    Rouge, Thibault De La Motte
    Vauthier, Jean-Michel
    Decrop, Maylis
    Pujol, Pascal
    CANCER RESEARCH, 2022, 82 (04)
  • [28] The pathology of familial breast cancer:: Predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2
    Lakhani, SR
    van de Vijver, MJ
    Jacquemier, J
    Anderson, TJ
    Osin, PP
    McGuffog, L
    Easton, DF
    JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (09) : 2310 - 2318
  • [29] Expansion cohort of Phase I study of oral sapacitabine and oral seliciclib in patients with metastatic breast cancer and BRCA1/2 mutations
    Keenan, Tanya
    Liu, David
    Elmarakeby, Haitham
    Stover, Daniel
    Kochupurakkal, Bose
    Tracy, Adam
    Danielczyk, Elaine
    Anderson, Leilani
    Andrews, Chelsea
    Reardon, Brendan
    Overmoyer, Beth
    Winer, Eric
    Zheleva, Daniella
    Chiao, Judy
    Blake, David
    Van Allen, Eliezer
    Shapiro, Geoffrey I.
    Tolaney, Sara
    CANCER RESEARCH, 2019, 79 (13)
  • [30] Final results of a phase 1 study of single-agent veliparib (V) in patients (pis) with either BRCA1/2-mutated cancer (BRCA plus ), platinum-refractory ovarian, or basal-like breast cancer (BRCA-wt).
    Puhalla, Shannon
    Beumer, Jan Hendrik
    Pahuja, Shalu
    Appleman, Leonard Joseph
    Tawbi, Hussein Abdul-Hassan
    Stoller, Ronald G.
    Lee, James J.
    Lin, Yan
    Kiesel, Brian
    Yu, Jing
    Tan, Antoinette R.
    Belani, Chandra Prakash
    Chew, Helen K.
    Garcia, Agustin A.
    Morgan, Robert
    Giranda, Vincent L.
    Shepherd, Stacie Peacock
    Chen, Alice P.
    Chu, Edward
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345